The ROE as of November 2024 (TTM) for Puma Biotechnology, Inc. (PBYI) is 41.50%

According to Puma Biotechnology, Inc.’s latest financial reports and current stock price. The company's current ROE is 41.50%. This represents a change of 406.77% compared to the average of 8.19% of the last 4 quarters.

Puma Biotechnology, Inc. (PBYI) Historical ROE (quarterly & annually)

How has PBYI ROE performed in the past?

The mean historical ROE of Puma Biotechnology, Inc. over the last ten years is 53.64%. The current 41.50% ROE has changed -22.63% with respect to the historical average. Over the past ten years (40 quarters), PBYI's ROE was at its highest in in the September 2020 quarter at 6.95%. The ROE was at its lowest in in the March 2020 quarter at -180.58%.

Puma Biotechnology, Inc. (PBYI) ROE by Quarter and Year

Discovering the peaks and valleys of Puma Biotechnology, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Puma Biotechnology, Inc. (PBYI) Average ROE

How has PBYI ROE performed in the past?

The current ROE of Puma Biotechnology, Inc. (PBYI) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Puma Biotechnology, Inc. (PBYI) ROE vs. Peers

How is PBYI’s ROE compared to its peers?

Puma Biotechnology, Inc.’s ROE is greater than Ultragenyx Pharmaceutical Inc. (-187.12%), greater than Crinetics Pharmaceuticals, Inc. (-36.12%), greater than Arvinas, Inc. (-50.26%), greater than Revolution Medicines, Inc. (-33.67%), greater than Kura Oncology, Inc. (-44.09%), greater than 2seventy bio, Inc. (-40.86%), greater than Intercept Pharmaceuticals, Inc. (-12.41%), greater than Iovance Biotherapeutics, Inc. (-58.43%), less than Sarepta Therapeutics, Inc. (11.83%), greater than Madrigal Pharmaceuticals, Inc. (-71.78%), greater than Viking Therapeutics, Inc. (-12.73%), greater than Hepion Pharmaceuticals, Inc. (-505.74%), less than PTC Therapeutics, Inc. (48.38%), less than Heron Therapeutics, Inc. (76.79%), greater than Coherus BioSciences, Inc. (0.40%), greater than Larimar Therapeutics, Inc. (-35.87%), greater than MacroGenics, Inc. (-89.42%),

Build a custom stock screener for Puma Biotechnology, Inc. (PBYI) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Puma Biotechnology, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Puma Biotechnology, Inc. (PBYI) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Puma Biotechnology, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.